oxytocin intranasal / Teijin - LARVOL DELTA

Cerebral and extracerebral distribution of radioactivity associated with oxytocin in rabbits after intranasal administration: Comparison of TTA-121, a newly developed oxytocin formulation, with Syntocinon. (PubMed, PLoS One) - "Since the distribution profiles showed no notable differences in radioactivity between the olfactory bulb and trigeminal nerve, intranasally-administered oxytocin was probably transferred to the brain via both pathways. The results also showed an increase in radioactivity in the prefrontal area and the precuneus, which are probable sites of pharmacological action as shown in clinical studies using functional magnetic resonance imaging (fMRI), confirming that intranasally-administered oxytocin could reach these tissues."

Journal • Preclinical • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Psychiatry • MRI

[VIRTUAL] TTA-121, A NOVEL OXYTOCIN NASAL SPRAY, IMPROVES ABDOMINAL PAIN IN A RAT IRRITABLE BOWEL SYNDROME MODEL (UEGW 2020) - "1 hour before the restraint stress exposure, rats received an intranasal treatment of vehicle or oxytocin formulation (TTA-121, 25 µL/body, Teijin Pharma Ltd.), or an oral treatment of ramosetron, a commercially available drug for IBS. This study shows that TTA-121 improves abdominal pain in IBS model. Our intranasal oxytocin formulation is expected to be a novel therapeutic option for IBS."

Preclinical • Fibromyalgia • Gastrointestinal Disorder • Immunology • Musculoskeletal Pain • Pain • Rheumatology

[VIRTUAL] TTA-121, A NOVEL OXYTOCIN NASAL SPRAY, IMPROVES ABDOMINAL PAIN IN A RAT IRRITABLE BOWEL SYNDROME MODEL (UEGW 2020) - "1 hour before the restraint stress exposure, rats received an intranasal treatment of vehicle or oxytocin formulation (TTA-121, 25 µL/body, Teijin Pharma Ltd.), or an oral treatment of ramosetron, a commercially available drug for IBS. This study shows that TTA-121 improves abdominal pain in IBS model. Our intranasal oxytocin formulation is expected to be a novel therapeutic option for IBS."

Preclinical • Fibromyalgia • Gastrointestinal Disorder • Immunology • Musculoskeletal Pain • Pain • Rheumatology

[VIRTUAL] TTA-121, A NOVEL OXYTOCIN NASAL SPRAY, IMPROVES ABDOMINAL PAIN IN A RAT IRRITABLE BOWEL SYNDROME MODEL (UEGW 2020) - "1 hour before the restraint stress exposure, rats received an intranasal treatment of vehicle or oxytocin formulation (TTA-121, 25 µL/body, Teijin Pharma Ltd.), or an oral treatment of ramosetron, a commercially available drug for IBS. This study shows that TTA-121 improves abdominal pain in IBS model. Our intranasal oxytocin formulation is expected to be a novel therapeutic option for IBS."

Preclinical • Fibromyalgia • Gastrointestinal Disorder • Immunology • Musculoskeletal Pain • Pain • Rheumatology